Department of Neurosurgery, Tianshui First People's Hospital, Tianshui, China.
Department of Neurosurgery, The Second Affiliated Hospital of Lanzhou University, Lanzhou, China.
Oncol Res. 2024 Apr 23;32(5):933-941. doi: 10.32604/or.2023.042581. eCollection 2024.
MicroRNA (miR)-200b-3p has been associated with many tumors, but its involvement in pituitary adenoma is unclear. This study investigated the molecular mechanism underlying miR-200b-3p regulation in pituitary adenomas to provide a theoretical basis for treatment. Bioinformatics was used to analyze pituitary adenoma-related genes and screen new targets related to RECK and miRNA. As well, the relationship between miR-200b-3p and RECK protein was verified using a double-luciferase reporter gene assay. The expression of miR-200b-3p in clinical samples was analyzed by hybridization. Transfection of the miR-200b-3p inhibitor and small interfering-RECK (si-RECK) was verified by qPCR. GH3 cell viability and proliferation were detected using CCK8 and EdU assays. Apoptosis was detected by flow cytometry and western blotting. Wound healing and Transwell assays were used to detect cell migration and invasion. The effects of miR-200b-3p and RECK on GH3 cells were verified using salvage experiments. miR-200b-3p was highly expressed in pituitary tumor tissue. Inhibitors of miR-200b-3p inhibited cell proliferation promoted cell apoptosis, inhibited invasion and migration, and inhibited the expression of matrix metalloproteinases. Interestingly, miR-200b-3p negatively regulated RECK. The expression of RECK in pituitary adenoma tissues was lower than that in neighboring tissues. Si-RECK rescued the function of miR-200b-3p inhibitors in the above cellular behaviors, and miR-200b-3p accelerated the development of pituitary adenoma by negatively regulating RECK expression. In summary, this study investigated the molecular mechanism by which miR-200b-3p regulates the progression of pituitary adenoma through the negative regulation of RECK. The findings provide a new target for the treatment of pituitary adenoma.
微小 RNA(miR)-200b-3p 与许多肿瘤有关,但它在垂体腺瘤中的作用尚不清楚。本研究旨在探讨 miR-200b-3p 调节垂体腺瘤的分子机制,为治疗提供理论依据。通过生物信息学分析,筛选出与 RECK 和 miRNA 相关的新靶点。利用双荧光素酶报告基因实验验证 miR-200b-3p 与 RECK 蛋白的关系。采用杂交技术分析临床样本中 miR-200b-3p 的表达。通过 qPCR 验证 miR-200b-3p 抑制剂和小干扰 RECK(si-RECK)的转染。采用 CCK8 和 EdU 检测 GH3 细胞活力和增殖。采用流式细胞术和 Western blot 检测细胞凋亡。通过划痕愈合和 Transwell 实验检测细胞迁移和侵袭。通过挽救实验验证 miR-200b-3p 和 RECK 对 GH3 细胞的影响。miR-200b-3p 在垂体瘤组织中高表达。miR-200b-3p 抑制剂抑制细胞增殖,促进细胞凋亡,抑制侵袭和迁移,抑制基质金属蛋白酶的表达。有趣的是,miR-200b-3p 负调控 RECK。垂体腺瘤组织中 RECK 的表达低于相邻组织。si-RECK 挽救了 miR-200b-3p 抑制剂在上述细胞行为中的作用,miR-200b-3p 通过负调控 RECK 表达加速了垂体腺瘤的发展。综上所述,本研究通过负调控 RECK 探讨了 miR-200b-3p 调节垂体腺瘤进展的分子机制。研究结果为垂体腺瘤的治疗提供了新的靶点。